Alnylam Forms UCSF Collaboration


Alnylam Pharmeceuticals (NASDAQ:ALNY), a Cambridge, MA-based developer of RNA-interference (RNAi) drugs, says it has formed a collaboration with the University of California, San Francisco, to explore the use of RNAi therapeutics to treat eye tumors. In previous research, scientists have found that RNAi treatments silenced a gene linked to the survival of eye tumor cells.

By posting a comment, you agree to our terms and conditions.